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Solid-Organ Transplantation in HIV-Infected Patients
Abstract
Before the introduction of highly active antiretroviral therapy in the mid-1990s, transplantation centers were
understandably reluctant to provide scarce solid organs for patients infected with the human
immunodeficiency virus (HIV). However, because treated patients can now expect to live substantially longer
than before, many will have end-stage organ disease long before they have life-threatening conditions related
to HIV infection. It is therefore time for the transplantation community to readdress the safety, efficacy, and
propriety of transplanting scarce organs in HIV-positive patients who need them.
In this article, we provide ethical arguments for viewing transplantation in patients with HIV infection as
analogous to transplantation in patients with other chronic illnesses. Accordingly, transplantation in HIV-
positive patients should be initiated at major centers and should not be considered experimental. In addition,
reimbursement for such procedures should be similar to that for transplantation in other patients, unless
evidence accumulates that HIV-infected transplant recipients fare poorly.
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 TRANSPLANTATION 
IN HIV-INFECTED PATIENTS
EFORE the introduction of highly active antiret-
roviral therapy in the mid-1990s, transplantation
centers were understandably reluctant to provide scarce
solid organs for patients infected with the human im-
munodeficiency virus (HIV). However, because treat-
ed patients can now expect to live substantially longer
than before,1-3 many will have end-stage organ disease
long before they have life-threatening conditions re-
lated to HIV infection.4 It is therefore time for the
transplantation community to readdress the safety, ef-
ficacy, and propriety of transplanting scarce organs in
HIV-positive patients who need them.
In this article, we provide ethical arguments for
viewing transplantation in patients with HIV infec-
tion as analogous to transplantation in patients with
other chronic illnesses. Accordingly, transplantation
in HIV-positive patients should be initiated at major
centers and should not be considered experimental. In
addition, reimbursement for such procedures should
be similar to that for transplantation in other patients,
unless evidence accumulates that HIV-infected trans-
plant recipients fare poorly.
CURRENT PRACTICES
Although the United Network for Organ Sharing
states that asymptomatic HIV-positive patients “should
not necessarily be excluded from candidacy for organ
transplantation,”5 most centers are concerned that
transplantation might harm HIV-positive patients and
believe that scarce organs should not be allocated to
patients with a poor prognosis.6 In a 1997 survey of
directors of U.S. renal-transplantation centers, 88 per-
cent of respondents indicated that they would not
consider transplanting an organ in a patient with
“asymptomatic HIV-infection who is otherwise a
good candidate for transplantation.”6 An earlier survey
of Canadian transplantation centers revealed similar
views.7 Only a small proportion of U.S. transplanta-
tion centers have agreed to participate in a proposed
multicenter study of transplantation in HIV-positive
patients. There is evidence that most patients and nurs-
es also believe that HIV-positive patients should not be
considered for heart transplantation.8 Moreover, in-
surance companies have generally refused to pay for
liver transplantation in HIV-infected patients.9-11 
ETHICAL CONSIDERATIONS
Even before the introduction of highly active anti-
retroviral therapy, a positive test for antibodies against
B
HIV was rarely, if ever, a legitimate criterion for with-
holding medical interventions other than transplanta-
tion. However, transplantation differs from other in-
terventions with regard to both ethical and medical
considerations. Because transplantable organs are
scarce, determining the most ethical allocation system
requires simultaneous considerations of efficacy, ur-
gency, and equity.12 
There are two distinct ethical questions about effi-
cacy: Does transplantation benefit the individual pa-
tients? Would it benefit other patients more? With
regard to the first question — the question of absolute
efficacy — transplantation can certainly help HIV-pos-
itive patients with end-stage organ disease.13-23 The
second question — concerning relative efficacy — is
rarely addressed in the distribution of plentiful re-
sources, but there is a strong moral basis for posing
this question when scarce resources are being allocat-
ed.24,25 We do not ask whether elderly persons should
receive antihypertensive therapy, even though the ben-
efits of long-term treatment are greater for younger
persons. However, if transplantation provided sub-
stantially less benefit, in terms of survival and quality
of life, for HIV-positive patients, then a policy of pref-
erential allocation of organs to HIV-negative patients
might be tenable.
Considerations of efficacy are factored into the al-
location policies of the United Network for Organ
Sharing in two ways: priority is given to candidates
whose ABO blood group matches that of a donor, and
in the case of kidney transplantation, HLA matching
is an additional consideration.5 With the availability
of highly active antiretroviral therapy, is it reasonable
to suppose that HIV status might still influence ef-
ficacy as much as genetic compatibility?
Though there has been no systematic comparison
of outcomes between HIV-positive and HIV-nega-
tive organ recipients, recent experience suggests that
large differences are unlikely. All published reports
of transplantation in HIV-positive patients who are
receiving multidrug antiretroviral regimens have con-
cluded that, in most cases, HIV infection does not
affect the outcome of transplantation.20-23 There are
several other, unpublished reports of favorable out-
comes several years after transplantation in HIV-pos-
itive patients receiving antiretroviral therapy (Olthoff
K: personal communication; and Stock P: personal
communication).
Even if HIV-positive transplant recipients proved to
have somewhat worse outcomes than HIV-negative re-
cipients, relative efficacy is not the sole ethical criterion
for determining candidacy. Medical urgency is another
important criterion in heart, lung, and liver transplan-
tation. This helps explain why patients who require
rapid retransplantation routinely receive it,24 even
though expected survival is markedly diminished.24,26,27
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Equity (equal access to organs among patients with
equivalent need) is also recognized as important by
both transplantation specialists and the public.28,29
Thus, most programs offer organs to patients infected
with hepatitis C virus (HCV), patients with diabetes,
older patients (up to a point), and black patients, de-
spite clear evidence that post-transplantation survival
is diminished in each of these groups.30-38 On ethical
grounds alone, there is no justification for providing
organs to these groups of patients but not to patients
infected with HIV.
MEDICAL CONSIDERATIONS
Might the questionable safety of transplantation in
HIV-positive patients justify the discriminatory allo-
cation system? There is an intuitive concern that im-
munosuppressive therapy might hasten the progres-
sion of HIV disease. However, the experience to date
suggests that the use of standard immunosuppressive
agents in patients with well-controlled HIV infec-
tion does not increase their susceptibility to oppor-
tunistic infections or malignant conditions.20,21,23 In
fact, two common immunosuppressive agents, cyclo-
sporine and tacrolimus, may actually improve out-
comes in HIV-positive transplant recipients by in-
hibiting interleukin-2–dependent T-cell replication,
by directly inhibiting HIV replication, or both.39,40
There is also concern about potential interactions
between antiretroviral and immunosuppressive agents.
Protease inhibitors increase blood concentrations of
tacrolimus and cyclosporine by inhibiting specific cy-
tochrome P-450 enzymes.41,42 However, experienced
centers routinely monitor blood levels of these agents
and adjust doses accordingly. The pharmacokinetics
of these interactions are similar to those in transplant
recipients who require other concomitant medications
(e.g., phenytoin) that may induce or inhibit the same
enzymes.
Finally, physicians have been concerned that sur-
gery itself might accelerate the progression of HIV
disease. However, there is evidence that disease pro-
gression is unaffected by surgery, even major surgery
requiring cardiac bypass.43-45
CONCERN ABOUT INTRAOPERATIVE 
TRANSMISSION OF HIV
Another concern is that HIV-positive patients might
transmit the virus to members of the transplantation
team. However, the risk of patient-to-surgeon trans-
mission of HIV is extremely low and is substantially
lower than the risk of transmission of many other in-
fectious diseases, including HCV, which are present
in many patients who undergo surgery.46 Even if a
member of a transplantation team were exposed to
HIV, various postexposure regimens provide effec-
tive prophylaxis against infection.47,48
Many argue that physicians are obligated to accept
such small risks because of their unique responsibil-
ities and privileges.49-51 Indeed, several major medi-
cal associations, including the American College of
Surgeons, contend that individual physicians have a
duty to provide care to HIV-positive patients.52-54
There may also be a legal duty to provide treatment
because HIV-positive persons are covered under the
Americans with Disabilities Act.50,51
OTHER ARGUMENTS 
AGAINST TRANSPLANTATION 
IN HIV-POSITIVE PATIENTS 
Some may argue that it is wrong to expand the
pool of eligible patients when the supply of organs is
already inadequate. This argument erroneously as-
sumes that patients with longer-established rights to
receive organs should have priority over those with
rights that have been established more recently. Eq-
uity dictates that no group of patients be penalized
simply because medicine has only recently advanced
to a point at which they may benefit from transplan-
tation.
A final argument against transplanting organs in
HIV-positive patients is that HIV infection is often,
though by no means always, associated with intrave-
nous-drug use or high-risk sexual practices. Such as-
sociations, however, have never been a legitimate
reason to withhold medical interventions from pa-
tients.55,56 HCV is also commonly acquired through
intravenous-drug use, and hepatitis B virus (HBV) is
also commonly acquired through the same high-risk
sexual practices as those associated with the trans-
mission of HIV. Yet these diseases, along with alco-
holic liver disease, remain the most common indica-
tions for liver transplantation in the United States. It
is not the role of medicine to adjudicate the morality
of personal behavior through selective treatment of
life-threatening conditions.
THE BURDEN OF PROOF
It has been proposed that organs be offered to
HIV-positive patients only in well-controlled studies
until transplantation experts have shown that the out-
comes are similar to those for uninfected patients.
We disagree with this approach. Proof of relative ef-
ficacy has never been required for the initiation of
new surgical procedures or for the expansion of in-
dications for established procedures. There was cer-
tainly reason to suspect that HCV-positive patients
would fare less well after liver transplantation than
HCV-negative patients, but systematic comparisons
were not required before these patients could receive
organs in nonexperimental settings. It is therefore un-
just to require such proof before offering transplan-
tation to HIV-positive patients.
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Still, some documentation of relative efficacy will
eventually be needed to gain the acceptance of phy-
sicians, the public, and third-party payers. The best
approach is to perform a substantial number of trans-
plantations in HIV-positive patients at major centers
and to record all pertinent data from their experience
in widely accessible data bases. Investigators will then
be able to compare the outcomes for HIV-positive
transplant recipients with those for HIV-negative re-
cipients who have similar demographic and disease-
related characteristics. Such retrospective analyses are
precisely how we learned about outcomes in HCV-
positive patients.34,35
PROVISION OF “MARGINAL” ORGANS
A counterproposal is that HIV-positive patients
should first merit consideration for the transplanta-
tion of so-called marginal, or expanded-criteria, or-
gans — those harvested from older donors, donors
infected with HBV or HCV, and, as is increasingly
common in renal transplantation, donors with diabetes
or hypertension. The outcomes for recipients of mar-
ginal organs are typically worse than those for recip-
ients of “ideal” organs.57,58 Therefore, in the absence
of evidence that HIV-positive patients derive less
benefit from transplantation than their HIV-negative
counterparts, we see no justification for making HIV
seropositivity an indication to use less viable organs. If
an HIV-positive patient also happens to have a known
risk factor for a poorer outcome, such as advanced co-
existing disease or advanced age, then the use of a mar-
ginal organ should be considered in the same way as
it would for a similar HIV-negative patient.
A CALL FOR CONSISTENCY
We believe it would be wrong to transplant an or-
gan in a patient with terminal AIDS for the same rea-
son that it would be wrong to transplant an organ
in a patient with widely metastatic hepatocellular car-
cinoma: both patients would probably die from the
coexisting illness before receiving any appreciable ben-
efit from the new organ. However, a broad range of
patients who are at low risk for progression to AIDS
or AIDS-related death can be identified with the use
of base-line CD4+ T-lymphocyte counts and HIV
RNA levels.59 Furthermore, because changes in the
viral load after the initiation of therapy also predict
progression to AIDS,60 even patients who at one time
met the diagnostic criteria for AIDS may benefit from
transplantation if they subsequently receive treatment
that provides good control of the disease.20 Trans-
plantation physicians must often make difficult deci-
sions about how various coexisting conditions influ-
ence the likelihood that a patient will benefit from
transplantation. The extent of HIV disease is simply
another coexisting condition to consider.
Now is the time to remove barriers to transplan-
tation in HIV-positive patients for whom it is other-
wise indicated. We should not wait for evidence of
relative efficacy to emerge. As with any new patient
population, accumulating data will inform future
analyses of the appropriateness of transplantation in
HIV-positive patients.
Current considerations of efficacy in organ alloca-
tion can be summarized as follows. We have substan-
tial evidence of diminished survival among HCV-pos-
itive patients, patients with diabetes, black patients,
and patients requiring retransplantation, yet we do
not prevent transplantation in these groups. In con-
trast, we have no evidence of poorer survival among
otherwise healthy HIV-positive patients who are re-
ceiving antiretroviral therapy, yet both overt and co-
vert barriers to transplantation remain. This contra-
diction is not justifiable according to any ethical
theory. Instead, it indicates yet another way in which
we continue to discriminate against HIV-positive
persons.
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